Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA, 02215, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
Sci Rep. 2021 Apr 21;11(1):8592. doi: 10.1038/s41598-021-87585-1.
A substantial number of subjects with Type 1 Diabetes (T1D) of long duration never develop albuminuria or renal function impairment, yet the underlying protective mechanisms remain unknown. Therefore, our study included 308 Joslin Kidney Study subjects who had T1D of long duration (median: 24 years), maintained normal renal function and had either normoalbuminuria or a broad range of albuminuria within the 2 years preceding the metabolomic determinations. Serum samples were subjected to global metabolomic profiling. 352 metabolites were detected in at least 80% of the study population. In the logistic analyses adjusted for multiple testing (Bonferroni corrected α = 0.000028), we identified 38 metabolites associated with persistent normoalbuminuria independently from clinical covariates. Protective metabolites were enriched in Medium Chain Fatty Acids (MCFAs) and in Short Chain Fatty Acids (SCFAs) and particularly involved odd-numbered and dicarboxylate Fatty Acids. One quartile change of nonanoate, the top protective MCFA, was associated with high odds of having persistent normoalbuminuria (OR (95% CI) 0.14 (0.09, 0.23); p < 10). Multivariable Random Forest analysis concordantly indicated to MCFAs as effective classifiers. Associations of the relevant Fatty Acids with albuminuria seemed to parallel associations with tubular biomarkers. Our findings suggest that MCFAs and SCFAs contribute to the metabolic processes underlying protection against albuminuria development in T1D that are independent from mechanisms associated with changes in renal function.
相当数量的长期 1 型糖尿病(T1D)患者从未出现白蛋白尿或肾功能损害,但潜在的保护机制仍不清楚。因此,我们的研究包括 308 名 Joslin 肾脏研究受试者,他们患有长期(中位数:24 年)1 型糖尿病,肾功能正常,在代谢组学测定前 2 年内,既有正常白蛋白尿,也有广泛的白蛋白尿范围。对血清样本进行了全面代谢组学分析。在至少 80%的研究人群中检测到 352 种代谢物。在经过多次测试调整的逻辑分析(Bonferroni 校正的 α = 0.000028)中,我们确定了 38 种代谢物与持续的正常白蛋白尿独立于临床协变量相关。保护代谢物在中链脂肪酸(MCFAs)和短链脂肪酸(SCFAs)中丰富,特别是涉及奇数和二羧酸脂肪酸。壬酸的四分之一变化,顶级保护 MCFA,与持续正常白蛋白尿的高几率相关(OR(95%CI)0.14(0.09,0.23);p < 10)。多变量随机森林分析也表明 MCFAs 是有效的分类器。相关脂肪酸与白蛋白尿的关联似乎与与肾功能变化相关的机制平行。我们的研究结果表明,MCFAs 和 SCFAs 有助于 T1D 中保护机制免受白蛋白尿发展的代谢过程,与肾功能变化相关的机制无关。